4P025
Primary Sclerosing Cholangitis (PSC)
DiscoveryActive
Key Facts
About 4P-Pharma
4P-Pharma is a Lille-based biotech leveraging an innovative partnership and Single Product Vehicle (SPV) model to de-risk and accelerate drug development. Its pipeline includes a Phase II asset for osteoarthritis and a discovery program for primary sclerosing cholangitis, targeting large and rare disease markets, respectively. The company combines in-house CRO-like expertise with open innovation sourcing, has raised over €20M, and operates with a team of 25+ across two sites in France.
View full company profileOther Primary Sclerosing Cholangitis (PSC) Drugs
| Drug | Company | Phase |
|---|---|---|
| PRO-PSC-001 | ProdIgY Biotech | Discovery |
| ORBCEL™ for Primary Sclerosing Cholangitis | Orbsen Therapeutics | Pre-clinical/Research |
| Volixibat | Mirum Pharmaceuticals | Phase 2b |
| Elafibranor (GFT505) | Genfit | Phase 2 |
| Bexotegrast (PLN-74809) | Pliant Therapeutics | Phase 2a |